<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04712864</url>
  </required_header>
  <id_info>
    <org_study_id>LB1901-TCL-1001</org_study_id>
    <nct_id>NCT04712864</nct_id>
  </id_info>
  <brief_title>Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma</brief_title>
  <official_title>A Phase 1, First-In-Human, Open-Label, Multicenter, Multicohort Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Legend Biotech USA Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Legend Biotech USA Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, first-in-human (FIH), open-label, multicenter, study of LB1901&#xD;
      administered to adult subjects with histologically confirmed CD4+ relapsed or refractory&#xD;
      Peripheral T-cell lymphoma (PTCL) (PTCL not otherwise specified [PTCL-NOS] and&#xD;
      angioimmunoblastic [AITL]), or relapsed or refractory cutaneous T-cell lymphoma (CTCL)&#xD;
      (Sézary syndrome [SS] and mycosis fungoides [MF]).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design: This is a Phase 1, first-in-human (FIH), open-label, multicenter, multicohort&#xD;
      study of LB1901 administered to adult subjects with histologically confirmed CD4+ relapsed or&#xD;
      refractory Peripheral T-cell lymphoma (PTCL) (PTCL not otherwise specified [PTCL-NOS] and&#xD;
      angioimmunoblastic [AITL]), or relapsed or refractory cutaneous T-cell lymphoma (CTCL)&#xD;
      (Sézary syndrome [SS] and mycosis fungoides [MF]).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 13, 2021</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To characterize the safety and tolerability of LB1901 and determine the optimal dose or recommended dose for expansion (RDE).</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Multiple doses will be tested to establish a recommended dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To further characterize the safety and tolerability of LB1901 with the RDE identified in the dose escalation and determine the recommended Phase 2 dose (RP2D).</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Treatment of additional patients at the recommended dose as identified in the initial dose escalation part of the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Over all Response</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Based on International Working Group Response Criteria for PTCL. Global Composite Response for CTCL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (TTR)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Based on International Working Group Response Criteria for PTCL. Global Composite Response for CTCL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Based on International Working Group Response Criteria for PTCL. Global Composite Response for CTCL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Based on International Working Group Response Criteria for PTCL. Global Composite Response for CTCL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Based on International Working Group Response Criteria for PTCL. Global Composite Response for CTCL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Based on International Working Group Response Criteria for PTCL. Global Composite Response for CTCL</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>T-Cell Lymphoma</condition>
  <condition>Peripheral T-Cell Lymphoma Refractory</condition>
  <condition>Cutaneous T-Cell Lymphoma Refractory</condition>
  <condition>Cutaneous T-Cell Lymphoma Recurrent</condition>
  <condition>Peripheral T-Cell Lymphoma Recurrent</condition>
  <arm_group>
    <arm_group_label>Experimental LB1901</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: anti-CD4 CAR T cells anti-CD4 CAR T cells transduced with a lentiviral vector to express CD4 chimeric receptor domain on T cells.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LB1901</intervention_name>
    <description>LB1901 - an autologous CD4-targeted CAR-T immunotherapy</description>
    <arm_group_label>Experimental LB1901</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent.&#xD;
&#xD;
          2. Subjects ≥ 18 years of age.&#xD;
&#xD;
          3. Histologically confirmed diagnosis of CD4+ PTCL-NOS; OR CD4+ AITL; OR CD4+ CTCL(either&#xD;
             MF or SS).&#xD;
&#xD;
          4. Relapsed or refractory disease with at least two prior lines of systemic&#xD;
             antineoplastic therapy.&#xD;
&#xD;
               -  Subjects with confirmed CD30+ PTCL or MF must have previously received&#xD;
                  brentuximab vedotin.&#xD;
&#xD;
               -  Subjects should have received at least two prior lines of standard of care&#xD;
                  therapies.&#xD;
&#xD;
          5. For Subjects with PTCL-NOS or AITL, at least one measurable lesion according to the&#xD;
             International Working Group (IWG) Response Criteria.&#xD;
&#xD;
          6. For subjects with CTCL, disease stage IIB or higher based on TNMB system.&#xD;
&#xD;
          7. Subjects must have an identified hematopoietic stem cell transplant (HSCT) donor&#xD;
             available prior to enrollment. HLA typing may be performed for source identification.&#xD;
&#xD;
          8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.&#xD;
&#xD;
          9. Adequate organ function.&#xD;
&#xD;
         10. Women of childbearing potential must have a negative pregnancy test at screening.&#xD;
&#xD;
         11. All Subject must agree to practice a highly effective method of contraception.&#xD;
&#xD;
         12. Women and men must agree not to donate eggs (ova, oocytes) or sperm, respectively,&#xD;
             until at least 1 year after receiving a LB1901.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed CD8+ TCL - CD8 positivity in tumor must be confirmed within 3&#xD;
             months prior to apheresis by IHC or flow cytometry.&#xD;
&#xD;
          2. Prior treatment with cellular immunotherapy (e.g., CAR-T) or gene therapy product&#xD;
             directed at any target.&#xD;
&#xD;
          3. Prior treatment with CD4-targeted therapy.&#xD;
&#xD;
          4. History of allogeneic haematopoietic stem cells transplant.&#xD;
&#xD;
          5. Antitumor therapy prior to apheresis as follows:&#xD;
&#xD;
               -  Any systemic anticancer therapy (chemotherapy, targeted therapy including ADC,&#xD;
                  epigenetic therapy including HDAC inhibitor, retinoids, pralatrexate, proteasome&#xD;
                  inhibitor therapy, investigational drug) within 21 days or at least 5 half-lives,&#xD;
                  whichever is shorter.&#xD;
&#xD;
               -  Anti-CCR4 monoclonal antibody or any other monoclonal antibody within 4 weeks or&#xD;
                  at least 5 half-lives, whichever is shorter.&#xD;
&#xD;
               -  Cytotoxic therapy within 14 days.&#xD;
&#xD;
               -  Immunomodulatory agent therapy within 7 days.&#xD;
&#xD;
               -  Radiotherapy within 14 days.&#xD;
&#xD;
          6. Immunosuppressant (e.g., cyclosporine or systemic steroids) above physiologic dosing&#xD;
             within 7 days of apheresis.&#xD;
&#xD;
          7. Therapeutic anticoagulants (such as warfarin, heparin, low molecular weight heparin)&#xD;
             (at least 3 half-lives must have elapsed after the last dose at the time of&#xD;
             apheresis).&#xD;
&#xD;
          8. CNS disease prophylaxis (e.g., intrathecal methotrexate) at least 7 days before&#xD;
             apheresis.&#xD;
&#xD;
          9. History or active Hepatitis B or C infection (except hepatitis C cured with&#xD;
             pharmacotherapy); or history of or current HIV infection.&#xD;
&#xD;
         10. History of autoimmune disease requiring systemic immunosuppression/systemic disease&#xD;
             modifying agents within the last 2 years.&#xD;
&#xD;
         11. Primary immunodeficiency.&#xD;
&#xD;
         12. Active CNS disease related to the underlying malignancy.&#xD;
&#xD;
         13. Stroke or seizure within 6 months of apheresis.&#xD;
&#xD;
         14. Impaired cardiac function or clinically significant cardiac disease.&#xD;
&#xD;
         15. Previous or concurrent malignancy with the following exceptions:&#xD;
&#xD;
               -  Adequately treated basal cell or squamous cell carcinoma.&#xD;
&#xD;
               -  In situ carcinoma of the cervix or breast, treated curatively and without&#xD;
                  evidence of recurrence for at least 3 years prior to screening.&#xD;
&#xD;
               -  A primary malignancy which has been completely resected, or treated, and is in&#xD;
                  complete remission for at least 3 years prior to screening.&#xD;
&#xD;
         16. Serious and/or uncontrolled medical condition that, in the Investigator's judgment,&#xD;
             would cause unacceptable safety risk.&#xD;
&#xD;
         17. Ongoing toxicity from previous anticancer therapy that has not resolved to baseline&#xD;
             levels or to Grade 1 or less, except for alopecia, fatigue, nausea, and constipation.&#xD;
&#xD;
         18. Major surgery within 4 weeks prior to apheresis, or planned within 4 weeks after&#xD;
             LB1901 administration.&#xD;
&#xD;
         19. Contraindications or life-threatening allergies, hypersensitivity, or intolerance to&#xD;
             LB1901 or its excipients, including dimethyl sulfoxide; or to fludarabine,&#xD;
             cyclophosphamide, or tocilizumab.&#xD;
&#xD;
         20. Contraindication or life-threatening allergy to valacyclovir, unless another suitable&#xD;
             option of antiviral prophylaxis is identified after consultation with an Infectious&#xD;
             Disease specialist.&#xD;
&#xD;
         21. Pregnant or breast-feeding.&#xD;
&#xD;
         22. Plans to become pregnant or breastfeed, or father a child within 1 year after&#xD;
             receiving a LB1901 infusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Legend Biotech</last_name>
    <phone>1.732.317.5050</phone>
    <email>medical.information@legendbiotech.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 1, 2020</study_first_submitted>
  <study_first_submitted_qc>January 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2021</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

